Plerixafor: what we still have to learn

Bibliography

• Jantunen E, Varmavuo V. Plerixafor for mobilization of blood stem cells in autologous transplantation: an update. Expert Opin Biol Ther 2014;14(6):851-61
   PubMed Web of Science ®Google Scholar
• Lanza F, Lemoli RM, Olivieri A, et al. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion 2014;54(2):331-9
   PubMed Web of Science ®Google Scholar
• Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of ’poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012;47(3):342-51
   PubMed Web of Science ®Google Scholar
• Mohty M, Hübel K, Kröger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014;49(7):865-72
   PubMed Web of Science ®Google Scholar
• Awan F, Kochuparambil ST, Falconer DE, et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 2013;48(10):1279-84
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011;17(5):729-36
   PubMed Web of Science ®Google Scholar
• Lemoli RM. New strategies for stem cell mobilization. Mediterr J Hematol Infect Dis 2012;4(1):e2012066
   PubMedGoogle Scholar
• Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2014;164(1):113-23
   PubMed Web of Science ®Google Scholar
• Jantunen E, Varmavuo V. Plerixafor for mobilization of blood stem cells in autologous transplantation: an update. Expert Opin Biol Ther 2014;14(6):851-61
   PubMed Web of Science ®Google Scholar
• Vishnu P, Roy V, Paulsen A, et al. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012;52:55-62
   PubMed Web of Science ®Google Scholar
• Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013;19:87-93
   PubMed Web of Science ®Google Scholar
• Hundemer M, Engelhardt M, Bruckner T, et al. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma. J Clin Apher 2014;10.1002/jca.21323
   PubMed Web of Science ®Google Scholar
• Yuan S, Nademanee A, Kaniewski M, et al. Efficacy of just-in-time plerixafor rescue for Hodgkin’s lymphoma patients with poor peripheral blood stem cell mobilization. Transfusion 2014;54(8):2015-21
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Peters C, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49(6):744-50
   PubMed Web of Science ®Google Scholar
• Chambon F, Merlin E, Rochette E, et al. Mobilization of hematopoietic stem cells by plerixafor alone in children: a sequential Bayesian trial. Transfus Apher Sci 2013;49(3):453-8
   PubMed Web of Science ®Google Scholar
• Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005;89(4):229-35
   PubMed Web of Science ®Google Scholar
• Basak GW, Wiktor-Jedrzejczak W, Apperley JF, et al. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF. Bone Marrow Transplant 2012;47(7):1003-5
   PubMed Web of Science ®Google Scholar
• Gomes AL, Carvalho T, Serpa J, et al. Hypercholesterolemia promotes bone marrow cell mobilization by perturbing the SDF-1:CXCR4 axis. Blood 2010;115:3886-94
   PubMed Web of Science ®Google Scholar
• Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol 2004;22(6):1095-102
   PubMed Web of Science ®Google Scholar
• Mendez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008;4:442-7
   Web of Science ®Google Scholar
• Harvey RD, Kaufman JL, Johnson HR, et al. Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biol Blood Marrow Transplant 2013;19(9):1393-5
   PubMed Web of Science ®Google Scholar
• Lefrère F, Mauge L, Réa D, et al. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure. R Transfusion 2013;53(3):564-9
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009;11:992-1001
   PubMed Web of Science ®Google Scholar
• Taubert I, Saffrich R, Zepeda-Moreno A, et al. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Cytotherapy 2011;13:459-66
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Ma¨ntymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol 2012;89:128-35
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mäntymaa P, Silvennoinen R, et al. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion 2013;53(5):1024-32
   PubMed Web of Science ®Google Scholar
• Pabst C, Krosl J, Fares I, et al. Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat Methods 2014;11(4):436-42
   PubMed Web of Science ®Google Scholar
• Uy GL, Rettig MP, Motabi IH, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012;119(17):3917-24
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Panetta JC, Cross SJ, et al. Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia. Biol Blood Marrow Transplant 2014;20(8):1224-8
   PubMed Web of Science ®Google Scholar
• Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009;113(18):4341-51
   PubMed Web of Science ®Google Scholar
• Hauge AW, Haastrup EK, Sengeløv H, et al. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion 2014;54(4):1055-8
   PubMed Web of Science ®Google Scholar
• Lanza F, Campioni D, Hellmann A, et al. for the Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society (EBMT). Quality assessment of autologous hematopoietic blood progenitor and stem cell grafting: results of the EBMT registration study. Biol Blood Marrow Transplant 2013;19(12):1670-6
   PubMed Web of Science ®Google Scholar